{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:47:02Z","timestamp":1772225222878,"version":"3.50.1"},"reference-count":55,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abnoba GmbH Niefern-\u00d6schelbronn, Germany"},{"name":"Helixor GmbH Rosenfeld, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Real-world data (RWD) play a crucial role in identifying key subgroups and assessing multimodal oncology therapies, including integrative and palliative care. Immune checkpoint blockade (ICB) has improved survival, and its combination with complementary therapies like Viscum album L. extracts (VA) may enhance outcomes. This RWD study, based on the Network Oncology registry and ESMO-GROW guidelines, analyzed oncological patients receiving PD-1\/PD-L1 inhibitors alone or with Helixor\u00ae VA (HVA) extracts. Primary and secondary objectives were tolerability and overall survival. Statistical analyses included Kaplan\u2013Meier survival curves and Cox regression. Among 405 cancer patients, 344 received ICB alone (CTRL) and 61 received ICB + HVA (COMB). Lung cancer was predominant (78.6%). Adverse event-related discontinuation was lower in COMB (4.9% vs. 6.4%, p = 0.25). In non-small cell lung cancer (NSCLC) patients, the 3-year survival rate was significantly higher in COMB (34.3% vs. 17.2%, p = 0.02). In female NSCLC patients, COMB was significantly associated with a reduced death risk of 91.2% (aHR: 0.088; 95% CI: 0.009\u20130.783). Our RWD findings show the favorable tolerability of combinatorial ICB + HVA in several tumor entities and underscore its potential to improve survival in NSCLC particularly in female NSCLC patients, warranting further investigation.<\/jats:p>","DOI":"10.3390\/ijms26083669","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:18:36Z","timestamp":1744611516000},"page":"3669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined Immune Checkpoint Blockade and Helixor\u00ae Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW)"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-8290","authenticated-orcid":false,"given":"Anja","family":"Thronicke","sequence":"first","affiliation":[{"name":"Network Oncology Registry, Research Institute Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Interdisciplinary Oncological Centre, Hospital Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"},{"name":"Charit\u00e9 Fatigue Centrum, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Roos","sequence":"additional","affiliation":[{"name":"Interdisciplinary Oncological Centre, Hospital Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"W\u00fcstefeld","sequence":"additional","affiliation":[{"name":"Lung Cancer Center, Hospital Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Grah","sequence":"additional","affiliation":[{"name":"Lung Cancer Center, Hospital Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Johnson","sequence":"additional","affiliation":[{"name":"Network Oncology Registry, Research Institute Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-6209","authenticated-orcid":false,"given":"Friedemann","family":"Schad","sequence":"additional","affiliation":[{"name":"Network Oncology Registry, Research Institute Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"},{"name":"Interdisciplinary Oncological Centre, Hospital Havelh\u00f6he, Kladower Damm 221, 14089 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e184846","DOI":"10.1172\/JCI184846","article-title":"Checkpoint therapy in cancer treatment: Progress, challenges, and future directions","volume":"134","author":"Bicak","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_2","first-page":"451","article-title":"Immune checkpoint inhibitors: Breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_3","unstructured":"Huang, A., Wang, K., and Penn Medicine (2024). Combo Immunotherapy Makes Waves of Cancer-Fighting T Cells, Penn Medicine. Available online: https:\/\/www.pennmedicine.org\/news\/news-releases\/2024."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Schad, F., Thronicke, A., Hofheinz, R.-D., Matthes, H., and Grah, C. (2024). Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1\/PD-L1 Blockade: A Real-World Data Study. Cancers, 16.","DOI":"10.3390\/cancers16081609"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schad, F., Thronicke, A., Hofheinz, R.D., Klein, R., Grabowski, P., Oei, S.L., W\u00fcstefeld, H., and Grah, C. (2024). Immune Checkpoint Blockade Combined with AbnobaViscum\u00ae Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121713"},{"key":"ref_6","unstructured":"(2025, April 09). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplement\u00e4rmedizin in der Behandlung von Onkologischen PatientInnen, Langversion 2.0, 2024 AWMF Registernummer: 032\/055OL. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/komplementaermedizin\/."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Thronicke, A., Steele, M.L., Grah, C., Matthes, B., and Schad, F. (2017). Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement. Altern. Med., 17.","DOI":"10.1186\/s12906-017-2045-0"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11912-023-01492-4","article-title":"Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours","volume":"26","author":"Krell","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","first-page":"239","article-title":"Prospective observational study of advanced or metastatic NSCLC patients treated with Viscum album L. extracts in combination wih PD-1\/PD-L1 blockade (PHOENIX-III)","volume":"42","author":"Oei","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Loef, M., and Walach, H. (2020). Quality of life in cancer patients treated with mistletoe: A systematic review and meta-analysis. BMC Complement. Med. Ther., 20.","DOI":"10.1186\/s12906-020-03013-3"},{"key":"ref_11","first-page":"CD003297","article-title":"Mistletoe therapy in oncology","volume":"2008","author":"Horneber","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15347354221133561","DOI":"10.1177\/15347354221133561","article-title":"Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and Meta-Analysis","volume":"21","author":"Loef","year":"2022","journal-title":"Integr. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00432-024-05742-1","article-title":"Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival","volume":"150","author":"Hofinger","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e006454","DOI":"10.1136\/jitc-2022-006454","article-title":"High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: A real-world pan-tumor analysis","volume":"11","author":"Jung","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: Anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_16","first-page":"347","article-title":"Mistletoe extract in patients with advanced pancreatic cancer: A double-blind, randomized, placebo-controlled trial (MISTRAL)","volume":"121","author":"Wode","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_17","first-page":"303","article-title":"Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial","volume":"24","author":"Piao","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5893017","DOI":"10.1155\/2019\/5893017","article-title":"Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies","volume":"2019","author":"Oei","year":"2019","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"430518","DOI":"10.1155\/2014\/430518","article-title":"Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial","volume":"2014","author":"Zdrale","year":"2014","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/1534735410369673","article-title":"Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies","volume":"9","author":"Kienle","year":"2010","journal-title":"Integr. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Thronicke, A., Oei, S.L., Merkle, A., Matthes, H., and Schad, F. (2018). Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines, 5.","DOI":"10.3390\/medicines5030100"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schad, F., and Thronicke, A. (2023). Safety of Combined Targeted and Helixor\u00ae Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20032565"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1912869","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zou, K.H., and Berger, M.L. (2024). Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union. Bioengineering, 11.","DOI":"10.3390\/bioengineering11080784"},{"key":"ref_25","unstructured":"Your Say (2025, April 09). Best Practices for Clinical Registries While Leveraging Real World Evidence. PLOS, n.d. Available online: https:\/\/yoursay.plos.org\/."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Schad, F., and Thronicke, A. (2022). Real-World Evidence-Current Developments and Perspectives. Int. J. Environ. Res. Public Health, 19.","DOI":"10.20944\/preprints202207.0141.v1"},{"key":"ref_27","first-page":"456","article-title":"Real-world data and its potential in oncology: A review of the current landscape and future directions","volume":"39","author":"Hernandez","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"2078","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"382","author":"Gandhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000524184","article-title":"Viscum album L. Therapy in Oncology: An Update on Current Evidence","volume":"29","author":"Thronicke","year":"2022","journal-title":"Complement. Med. Res."},{"key":"ref_30","first-page":"22","article-title":"Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability","volume":"15","author":"Kuehn","year":"2008","journal-title":"Forsch. Komplementmed."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-023-02234-3","article-title":"Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: A real-world data study","volume":"18","author":"Schad","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1534735416681641","article-title":"Safety of Combined Treatment with Monoclonal Antibodies and Viscum album L Preparations","volume":"17","author":"Schad","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.5993\/AJHB.32.6.9","article-title":"Age-related differences in the conventional health care-complementary and alternative medicine link","volume":"32","author":"Grzywacz","year":"2008","journal-title":"Am. J. Health Behav."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.clon.2022.03.010","article-title":"Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated with PD-1\/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"34","author":"Madala","year":"2022","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gu, Y., Tang, Y.Y., Wan, J.X., Zou, J.Y., Lu, C.G., Zhu, H.S., Sheng, S.Y., Wang, Y.F., Liu, H.C., and Yang, J. (2022). Sex difference in the expression of PD-1 of non-small cell lung cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1026214"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ortona, E., Pierdominici, M., and Rider, V. (2019). Editorial: Sex Hormones and Gender Differences in Immune Responses. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01076"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Migliore, L., Nicol\u00ec, V., and Stoccoro, A. (2021). Gender Specific Differences in Disease Susceptibility: The Role of Epigenetics. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060652"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Klein, S.L., and Morgan, R. (2020). The impact of sex and gender on immunotherapy outcomes. Biol. Sex. Differ., 11.","DOI":"10.1186\/s13293-020-00301-y"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4274\/MNM.2024.24223","article-title":"Use of Complementary and Integrative Medicine in Women\u2019s Health: A Literature Review","volume":"4","author":"Denizer","year":"2024","journal-title":"Mediterr. Nurs. Midwifery"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1016\/j.ejca.2013.06.043","article-title":"Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival","volume":"49","author":"Galun","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schad, F., Thronicke, A., Steele, M.L., Merkle, A., Matthes, B., Grah, C., and Matthes, H. (2018). Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE, 13, Erratum in PLoS ONE\u00a02022, 17, e0273387.","DOI":"10.1371\/journal.pone.0273387"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Saha, C., Das, M., Stephen-Victor, E., Friboulet, A., Bayry, J., and Kaveri, S.V. (2016). Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4\u207a T Cell Responses. Molecules, 21, Erratum in Molecules\u00a02019, 24, 3762.","DOI":"10.3390\/molecules24203762"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ma, L., Phalke, S., Stevigny, C., Souard, F., and Vermijlen, D. (2020). Mistletoe-Extract Drugs Stimulate Anti-Cancer Vgamma9Vdelta2 T Cells. Cells, 9.","DOI":"10.3390\/cells9061560"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"Veninga","year":"2023","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"G\u00e9mes, N., Balog, J.\u00c1., Neuperger, P., Schlegl, E., Barta, I., Fillinger, J., Antus, B., Zvara, \u00c1., Heged\u0171s, Z., and Czimmerer, Z. (2023). Single-cell immunophenotyping revealed the association of CD4+ central CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1297577"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1989789","DOI":"10.1080\/2162402X.2021.1989789","article-title":"PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vgamma2Vdelta2 T cells against human prostate cancer","volume":"10","author":"Nada","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctcp.2019.01.004","article-title":"Complementary and alternative medicine use in cancer: A systematic review","volume":"35","author":"Keene","year":"2019","journal-title":"Complement. Ther. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mdi110","article-title":"Use of complementary and alternative medicine in cancer patients: A European survey","volume":"16","author":"Molassiotis","year":"2005","journal-title":"Ann Oncol."},{"key":"ref_50","first-page":"353","article-title":"Network Oncology (NO)\u2014A clinical cancer registry for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine","volume":"20","author":"Schad","year":"2013","journal-title":"Forsch. Komplementmed."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Pellat","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"key":"ref_53","unstructured":"R Core Team (2021). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_54","unstructured":"Gerds, T.A. (2025, April 09). prodlim: Product-Limit Estimation for Censored Event History Analysis. R Package, Version 2019.11.13. Available online: https:\/\/CRAN.R-project.org\/package=prodlim."},{"key":"ref_55","unstructured":"Kassambara, A., Kosinski, M., and Biecek, P. (2025, April 09). survminer: Drawing Survival Curves Using \u2018ggplot2\u2019. R Package Version 0.4.9. Available online: https:\/\/CRAN.R-project.org\/package=survminer."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/8\/3669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:30Z","timestamp":1760030010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/8\/3669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26083669"],"URL":"https:\/\/doi.org\/10.3390\/ijms26083669","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]}}}